| __timestamp | Bausch Health Companies Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 7461000 |
| Thursday, January 1, 2015 | 2682700000 | 11960000 |
| Friday, January 1, 2016 | 2810000000 | 13108000 |
| Sunday, January 1, 2017 | 2582000000 | 17501000 |
| Monday, January 1, 2018 | 2473000000 | 22472000 |
| Tuesday, January 1, 2019 | 2554000000 | 24286000 |
| Wednesday, January 1, 2020 | 2367000000 | 29689000 |
| Friday, January 1, 2021 | 2624000000 | 38837000 |
| Saturday, January 1, 2022 | 2625000000 | 47489000 |
| Sunday, January 1, 2023 | 2917000000 | 53379000 |
Infusing magic into the data realm
In the ever-evolving landscape of the pharmaceutical industry, operational efficiency is paramount. Over the past decade, Bausch Health Companies Inc. and Xencor, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Bausch Health, a giant in the sector, consistently reported SG&A expenses averaging around $2.57 billion annually, peaking at $2.92 billion in 2023. This reflects a steady growth of approximately 44% from 2014. In stark contrast, Xencor, a smaller biotech firm, maintained a more modest SG&A expenditure, starting at $7.46 million in 2014 and rising to $53.38 million by 2023, marking a significant increase of over 600%. This divergence highlights the varied approaches to operational costs, with Bausch focusing on scale and Xencor on strategic growth. As the industry continues to evolve, these insights offer a glimpse into the financial strategies shaping the future of healthcare.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Bausch Health Companies Inc.
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Bausch Health Companies Inc.
Cytokinetics, Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Bausch Health Companies Inc.
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Bausch Health Companies Inc. or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Galapagos NV
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.